Main description:

New in this edition:* New chapter on pharmacogenomics* New section with NbN (Neuroscience-based Nomenclature) classification ofpsychotropics* Substantial revisions of chapters on antipsychotics, BLT, rTMS, natural healthproducts* Substantially revised charts include: Relative tolerability profiles of antipsychotics; Laboratoryand clinical monitoring of antipsychotics; Comparison / doses / pharmacokinetics ofextrapyramidal agents* Drugs / classes / formulations* Unapproved treatments

Contents:

Table of Contents (preliminary):AntidepressantsSelective Serotonin Reuptake Inhibitors (SSRI) * Norepinephrine Dopamine Reuptake Inhibitor (NDRI) * Serotonin NorepinephrineReuptake Inhibitor (SNRI) * Serotonin-2 Antagonists/Reuptake Inhibitors (SARI) * Serotonin-1A Agonist/Serotonin Reuptake Inhibitor* Serotonin Stimulator / Serotonin Modulator * Noradrenergic/Specific Serotonergic Antidepressants (NaSSA) * Nonselective CyclicAntidepressants * Monoamine Oxidase Inhibitors * Reversible Inhibitor of MAO-A (RIMA) * Irreversible Monoamine Oxidase (A&B)Inhibitors (MAOIs) * Irreversible MAO-B Inhibitor * Effects of Antidepressants on Neurotransmitters/Receptors * Pharmacological Effectsof Antidepressants on Neurotransmitters/Receptors * Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses *Antidepressant Doses and Pharmacokinetics * Switching Antidepressants * Antidepressant Augmentation StrategiesElectroconvulsive Therapy (ECT)Bright Light Therapy (BLT)Repetitive Transcranial Magnetic Stimulation (rTMS)Antipsychotics"Second-Generation" Antipsychotics/SGAs * "Third-Generation" Antipsychotic/TGA * "First-Generation" Antipsychotics/FGAs * Effectsof Antipsychotics on Neurotransmitters/Receptors * Pharmacological Effects of Antipsychotics on Neurotransmitters/ReceptorSubtypes * Relative Tolerability Profiles of Antipsychotics * Frequency of Adverse Reactions to Antipsychotics at Therapeutic Doses *Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections) * Comparison of Long-Acting IM Antipsychotics * SwitchingAntipsychotics * Antipsychotic Augmentation StrategiesAntipsychotic-Induced Extrapyramidal Side Effects and Their ManagementExtrapyramidal Adverse Effects of Antipsychotics * Treatment Options for Extrapyramidal Side Effects * Effects on ExtrapyramidalSymptoms * Comparison of Agents for Treating Acute Extrapyramidal Side Effects * Doses and Pharmacokinetics of Agents for TreatingAcute Extrapyramidal Side EffectsAnxiolytic (Antianxiety) AgentsBenzodiazepines * Comparison of the Benzodiazepines * BuspironeHypnotics/SedativesL-Tryptophan * Comparison of Hypnotics/SedativesMood StabilizersLithium * Anticonvulsants * Comparison of Anticonvulsants * Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic DosesDrugs for ADHDPsychostimulants * Atomoxetine * Comparison of Drugs for ADHD * alpha2 Agonists * Augmentation Strategies in ADHDDrugs for Treatment of DementiaCholinesterase Inhibitors * Memantine * Comparison of Drugs for Treatment of DementiaSex-Drive DepressantsComparison of Sex-Drive DepressantsDrugs of AbuseAlcohol * Stimulants * Hallucinogens * Opioids * Inhalants/Aerosols * Gamma-hydroxybutyrate (GHB)/Sodium Oxybate * Flunitrazepam(Rohypnol) * Nicotine/TobaccoTreatment of Substance Use DisordersAcamprosate * Disulfiram * Naltrexone * Buprenorphine * Methadone * Pharmacotherapy for Nicotine/Tobacco Use DependenceUnapproved Treatments of Psychiatric DisordersAdrenergic Agents * Dopaminergic Agents * GABA Agents/Anticonvulsants * Hormones * NMDA Agents * MiscellaneousNatural Health ProductsPharmacogenomic Information for Common Psychiatric DrugsGlossaryResources for Information on Drug Use in Pregnancy and Effectson Breast MilkNeuroscience-Based NomenclaturePatient Information SheetsIndex of Drugs